Multiplier AI Blog
Know How Data, AI, & Digital Marketing Can Help Pharma & Life Sciences
Next Best Action Software for Life Sciences: The 2026 Buyer's Guide
Next best action is now the default vocabulary of pharma commercial operations. IQVIA analysis cited across the industry puts deployment at over 80% of major pharma companies running some form of next best action in the field, and McKinsey estimates AI could create $18–30 billion in annual value across pharma commercial functions. Yet walk into most commercial
Patient Intelligence Platforms: Key Features & Evaluation Checklist (2026)
Most hospitals already hold enough data to know which patients are about to stop coming back. The information sits in the HIS, the lab system, the pharmacy, the radiology module, the call centre log and the billing ledger — and almost none of it is connected to a single patient identity. The result is a hospital that can report yesterday's occupancy to two decimal places but cannot answer a sim
Scaling Personalized Physician Content: A Commercial Operations Guide (2026)
Every commercial operations lead in pharma has been handed the same instruction: make the content personal, make it omnichannel, and do it without adding headcount or breaking compliance. The instruction is reasonable. The way most organisations try to execute it is not. They take a content model built for a printed detail aid — one document, one approval, one audience — and ask it to produce t
Best Pharma CDP Platforms for HCP Data (2026)
There are roughly 208 active customer data platform vendors, and only 22% of marketers report high usage of the one they purchased. Those two numbers, taken together, describe a category where buying is much easier than benefiting. Pharmaceutical marketing teams are not exempt — if anything they are more exposed, because the pharma martech conversation routinely conflates five different things
Axtria vs ZS vs Agentic AI Platforms: Choosing a Commercial Partner
Most comparisons of Axtria and ZS treat the choice as a software decision — feature grids, deployment models, pricing structures. That framing was reasonable two years ago. It is now misleading, because within six months in late 2025 and early 2026 both firms answered a more fundamental question in the same way, and the answer changes what a buyer is actually choosing between.
Aktana Alternatives: Next Best Action Platforms Compared (2026)
Search volume for “Aktana alternatives” rose sharply after 7 January 2026, when PharmaForceIQ announced it had acquired Aktana in an asset acquisition with no financial terms disclosed. That timing tells you what most people typing the phrase are actually asking. They are not dissatisfied with the product — Aktana has been a recognised leader in this category for a decade, was named a Leader an
Customer Centricity in Pharma & Life Sciences
In March 2025 Deloitte published a finding that ought to have ended the debate about whether pharmaceutical companies are customer-centric. Eighty-two per cent of life sciences executives said they were satisfied with their organisation's customer engagement strategy. Twenty-eight per cent of healthcare professionals said those strategies met their needs. Both groups were describing the same ac
Territory Alignment in Pharma: A Practical Framework
Territory alignment is usually described as a mapping problem: draw boundaries so that each representative has a fair share of the work and a fair share of the opportunity. That description is accurate and it is why so many alignments fail. Balance is the easiest property to measure and the easiest to optimise, so it becomes the objective — while the property that actually generates revenue, th
Field Force Effectiveness & Sales Force Sizing in Pharma
Most field force effectiveness programmes measure the wrong thing, and most sales force sizing exercises answer a question that stopped being the right one somewhere around 2023. Both problems have the same root cause: the industry built its measurement and sizing logic in an era when a representative who made more calls reached more physicians, and reaching more physicians produced more prescr
Digital Marketing Analytics for Pharma Brands: From Dashboards to Decisions
Digital marketing analytics is the practice of collecting, connecting and interpreting data from every digital channel — email, web, paid media, events, portals and rep-triggered content — to measure what is working and decide what to do next. In pharma, it means linking HCP-level engagement signals to prescribing behaviour, so marketing spend and field effort can be directed at the physicians
TRx, NRx & NBRx Explained: The Pharma Prescription Metrics Glossary
If you work anywhere near pharma sales or analytics, three acronyms follow you everywhere: TRx, NRx, and NBRx. They look similar, they're often confused, and getting them wrong quietly distorts every sales report, incentive plan, and market-share slide built on top of them. This glossary explains each metric in plain language, shows exactly how they differ, and covers how to use them together t
-in-Pharma-Turning-Real-World-Data-into-Commercial-Advantage.webp)
Real-World Evidence (RWE) in Pharma: Turning Real-World Data into Commercial Advantage
Clinical trials tell you how a therapy performs under controlled conditions. Real-world evidence tells you how it performs in the messy reality of everyday practice — with real patients, real adherence, and real outcomes. For pharma commercial teams, that difference is where a growing share of competitive advantage now lives.